Coho Biologics

Coho Biologics operates as a specialized Contract Research Organization (CRO) providing analytical testing services, not as a drug developer. It serves biotech and pharma companies developing biologics, with a focus on RNA, proteins, and vaccines, offering services under FDA, cGMP, and GLP guidelines. The company leverages a team of seasoned scientists and advisors with deep industry experience to deliver rapid, accurate results for client programs in oncology and immunology. Its business model is service-based, generating revenue through testing contracts, positioning it in the growing outsourced pharma services market.

Integrated analytical testing services utilizing advanced immunoassays, particle sizing, and cell-based assays for the characterization of proteins, RNA, and nanoparticle formulations.

Coho competes in the fragmented bioanalytical testing market against large global CROs (e.g., LabCorp, Charles River, PPD) and numerous small-to-mid-sized specialty labs. Its differentiation hinges on deep expertise in RNA/proteins, rapid turnaround, and a personalized service model for biotech clients.